Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

REGENERON PHARMACEUTICALS INC

Form 4

March 11, 2011

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

Section 16.

Form 4 or

Form 5

Obligations

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations

obligations may continue.

See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * McCorkle Douglas S		ng Person *	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [REGN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner		
(Last) 777 OLD SAW ROAD	D SAW MILL RIVER	,	3. Date of Earliest Transaction (Month/Day/Year) 03/09/2011	X_ Officer (give title Other (specification) VP Controller and Asst Treasur		
TARRYTOWN	(Street) N. NY 1059	1	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting		
				Person		

(City)	(State) (Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securi on(A) or D (Instr. 3,	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/09/2011		M(1)	7,412	A	\$ 20.32	7,412	D	
Common Stock	03/09/2011		S <u>(1)</u>	7,412	D	\$ 40 (2)	0	D	
Common Stock	03/09/2011		M(1)	1,988	A	\$ 20.32	1,988	D	
Common Stock	03/09/2011		S(1)	1,988	D	\$ 40 (2)	0	D	
							4,120	I	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common By 401(k) Stock Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number proof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Shares
Incentive Stock Option (right to buy)	\$ 20.32	03/09/2011		M <u>(1)</u>	7,412	(3)	12/18/2016	Common Stock	7,41
Non-Qualified Stock Option (right to buy)	\$ 20.32	03/09/2011		M <u>(1)</u>	1,988	(3)	12/18/2016	Common Stock	1,98

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

McCorkle Douglas S 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

VP Controller and Asst Treasur

Signatures

/s/**Douglas S.
McCorkle
03/11/2011

**Signature of Reporting Date
Person

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- The reporting person sold a total of 9,400 shares of Company stock on March 9, 2011 at prices ranging from \$40.00 to 40.04. Upon (2) request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information
- regarding the number of shares sold by the reporting person on March 9, 2011 at each separate price.
- (3) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- (4) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.